We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

2 hedge funds and large institutions have $15K invested in Lexaria Bioscience Warrant in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

62% less capital invested

Capital invested by funds: $39.3K → $15K (-$24.3K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$380
2
CS
Clear Street
New York
-$76
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Heights Capital Management
California
$13.4K – – –
UBS Group
2
UBS Group
Switzerland
$1.58K -$380 -984 -19%
CS
3
Clear Street
New York
– -$76 -100 Closed

LEXXW Hedge Fund Activity: Q1 2025 in Review

2 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q1 2025, worth a combined $15K — down 62% from $39.3K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LEXXW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was UBS Group, cutting an estimated $380.

  • 2 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q1 2025, down from 3 in Q4 2024.
  • Funds reported $15K of Lexaria Bioscience Warrant stock for Q1 2025, down 62% quarter-over-quarter.
  • 0 funds opened new Lexaria Bioscience Warrant positions in Q1 2025 and 1 closed out, a net change of -1 holder.
  • The largest Lexaria Bioscience Warrant seller in Q1 2025 was UBS Group, an estimated $380 sold.

Based on aggregated 13F filings for Q1 2025.